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Mediastinal tumors, cysts, and other lesions can be diag-nosed using fluoroscopy, transthoracic ultrasound
(US), or computed tomography (CT)-guided biopsies, right,
left, and bilateral video-assisted thoracoscopic surgery
(VATS), anterior mediastinotomy, and minithoracotomy/
Chamberlain procedure.1 Biopsy specimens include fine-nee-
dle aspiration (FNA) biopsies, needle core biopsies, and
incisional biopsies.2–7 A detailed discussion of the technical
advantages and disadvantages of each diagnostic procedure is
beyond the scope of this document. In general, these proce-
dures are safe with complications such as pneumothorax,
bleeding, and others in less than 5% of patients. Nevertheless,
incidences of pneumothorax of up to 34% have been de-
scribed in patient undergoing transthoracic needle biopsies of
hilar lesions. Biopsies of mediastinal cystic lesions are gen-
erally approached with particular caution because of occa-
sional reports of infection after the procedure.6 Seeding of
the site after biopsies of thymomas has been limited to a
few rare cases.8,9
In general, mediastinal tumors located in the anterior
mediastinum are approached using transthoracic US or CT-
guided FNA and core needle biopsies or minithora-
cotomy.2,3,6,8–17 Middle mediastinal lesions can be diagnosed
using mediastinoscopy, endobronchial US-guided biopsy,
and transesophageal US-guided biopsy.17 Posterior mediasti-
nal lesions can be diagnosed using US- or CT-guided trans-
thoracic biopsies but often require VATS.18 Table 1 shows
the sensitivity and specificity of these various diagnostic
procedures.1–3,6,7,10–15,17,19–22
Progress in the field of mediastinal malignancies re-
quires widespread collaboration, which necessitate some con-
sistency in how specimens are handled, interpreted, and
reported. This article provides recommendations that should
serve as a framework for such consistency. This article refers
only to biopsy specimens obtained for diagnosis; specimens
obtained during a potentially curative resection are addressed
elsewhere.23 These standard policies are not meant to stifle
research or exploration of new methods; on the contrary, the
proposed recommendations are designed to facilitate this.
The standard operating procedures and policies outlined in
this study merely provide a baseline framework and should be
viewed as a minimal consistent standard that permits com-
parison of results from multiple institutions. These standards
have been adopted by members of the International Thymic
Malignancy Interest Group (ITMIG) for use in collective
initiatives. It is hoped that it will be used by others as well,
both in routine practice and in reporting in the literature.
METHODS
An initial workgroup consisting of pathologists and
surgeons (Alberto Marchevsky, Alexander Marx, Saul Suster,
Maureen Zakowski, Federico Venuta, Sam Youssem, and
Philipp Stro¨bel) was assembled to review literature relevant
to the issues and formulate preliminary recommendations.
These were refined after discussion in an ITMIG broad
multidisciplinary workshop meeting, which was supported by
the International Association for the Study of Lung Cancer. A
draft of this article, containing the proposed policies and
standard operating procedures, was then disseminated to all
ITMIG members for further discussion. With this input, this
article with the final recommendations was written and ulti-
mately approved for adoption by the ITMIG members for use
in ITMIG collaborative initiatives.
CORRELATING THE PATHOLOGICAL AND
CLINICO-RADIOLOGICAL FINDINGS
A detailed discussion of the differential diagnosis of
various mediastinal lesions is beyond the scope of this doc-
ument. It is often very helpful for pathologists to gather
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information regarding the age and gender of the patients and
the location and radiological appearance of lesions before
examination of biopsy materials. For example, if a child or
young adult in his or her second to third decade of life
presents with an anterior mediastinal mass, the differential
diagnosis would include germ cell tumors, cystic hygroma,
Hodgkin lymphoma, and lymphoblastic lymphoma, whereas
if the patient is older, the differential diagnosis would include
thymoma and other thymic epithelial lesions, mediastinal
B-cell lymphoma, and other malignancies.1 Lesions in the
upper anterior mediastinum are often of thyroid origin,
whereas tumors of the anterior mediastinum in adults with
myasthenia gravis are usually thymoma. Tumors and cysts in
the middle mediastinum often occur in adults and are Hodg-
kin or non-Hodgkin lymphomas and other lymphoid lesions,
mediastinal cysts, metastasis from lung or other cancers,
sclerosing mediastinitis, and other conditions.1 The differen-
tial diagnosis of posterior mediastinal lesions includes neu-
rogenic tumors, gastroenteric cysts, and other lesions.1
Table 2 provides a summary of primary mediastinal
lesions by location and age. Nevertheless, it is important for
pathologists to remember that the most common mediastinal
lesions remain metastases, often from lung primaries.
FNA BIOPSIES OF MEDIASTINAL LESIONS
Technical Aspects
There are no expert-consensus or evidence-based
guidelines or standards for the performance of mediastinal
biopsies. Most of the studies have reported good results for
transthoracic and other FNA procedures using 22-gauge nee-
dles.2–7 Therefore, we suggest that a reasonable minimal
baseline is the use of 22-gauge needles to obtain transthoracic
FNA biopsies (Table 3).
There are no expert-consensus or evidence-based
guidelines regarding the minimum number of passes required
to obtain adequate FNA samples, the number of smears, and
other slides that should be prepared and other technical
standards. It is important that smears stained with Diff-Quick
or other rapid staining procedure be evaluated by a cyto-
pathologist or cytotechnologist for adequacy at the time of
FNA procedures to ensure that the samples are sufficient for
diagnosis and additional studies.4,5 This is not possible in
some practice situations because of staff shortages or other
logistical considerations. In most patients, a minimum of
three biopsy passes is sufficient to prepare multiple smears
that can be stained with Diff-Quick, Papanicolau stain, and
various immunostains. In general, two or more smears should
be prepared per biopsy pass with the remainder of the
material placed in a collection fluid such as CYTORICH Red
(Thermo Fisher Scientific, Pittsburgh, PA) or others for cell
block preparation. We propose that these practices be adopted
as the standard policy for FNA biopsies.
FNA cytological samples are generally fixed in 95%
alcohol.4,5,7 There are no criteria for adequacy or of the
minimum number of slides needed. Generally, on-site eval-
TABLE 1. Sensitivity and Specificity of Mediastinal Biopsies
for the Diagnosis of Mediastinal Lesionsa
Biopsy Procedure Sensitivity (%) Specificity (%) PPV (%)
Transthoracic FNA 71–100 77–100 69–100
EBUS or EUS FNA 38–88 65–100 90–100
Percutaneous core biopsy 40–93 76–90 83–91
a Most studies report sensitivity and specificity values for various mediastinal
lesions and recognize that the diagnosis of thymoma can be difficult on FNA and needle
biopsies.1–3,6,7,10–15,17,19–22 Zakowski et al.7 have reported 100% accuracy for the
diagnosis of thymoma and thymic carcinomas using FNA.
EBUS, endobronchial ultrasound; EUS, esophageal ultrasound; FNA, fine-needle
aspiration; PPV, positive predictive value.
TABLE 2. Common Mediastinal Lesions by Location and
Age
Condition
Mediastinal
Location Age
Thymoma Anterior Adults
Thymic carcinoma Anterior Adults
Thymic hyperplasia Anterior Adults, children
Neuroendocrine neoplasms Anterior Adults
Germ cell tumors Anterior Children, young adults
Lymphoblastic lymphoma Anterior Children, adults
Hodgkin lymphoma Anterior, middle Children, adults
Diffuse large cell lymphoma Anterior Young adults
Thymolipoma Anterior Adults
Sclerosing mediastinitis Anterior, middle Adults
Castleman’s disease Anterior, middle Adults
Multilocular thymic cysts Anterior Adults
Congenital thymic cysts Anterior Children, young adults
Ectopic thyroid tumors Anterior Adults
Ectopic parathyroid tumors Anterior Adults
Paraganglioma Anterior Adults
Bronchogenic cysts Middle Adults
Mesothelial/pericardial cysts Middle Adults
Metastatic tumors Middle, anterior Adults
Neurogenic tumors Posterior Children, adults
Enteric cysts Posterior Adults
TABLE 3. Policies Regarding FNA Biopsies of Mediastinal
Lesions
Technical aspects when obtaining FNA biopsies
22-guage needle (or larger)
Either ROSE or at least three passes
Either ROSE or at least six smears (two smears per pass) and collection
of materials in CYTORICH Red collection fluid or similar solution
Preparation of a cell block is suggested
A sample for flow cytometry is recommended if lymphoma is suspected
Interpretation and reporting of FNA biopsies
Interpretation should be correlated with clinical and radiologic findings
Specimen adequacy should be reporteda
Immunostains should be used as suggested by the differential diagnosis
Consultation with an experienced second pathologist is recommended
whenever there is any diagnostic difficulty
a No general criteria are possible but should be assessed relative to the clinically
applicable differential diagnosis.
FNA, fine-needle aspiration; ROSE, real-time on-site examination.
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uation assures that enough material is obtained in most cases.
If this is not available, we suggest that a minimum number of
six smears (two per biopsy pass) should be prepared with
additional materials placed in appropriate collection fluids for
cell block preparation as explained earlier in the text. The
slides are usually stained with Diff-Quick, Papanicolau, and
hematoxylin and eosin (HE) stains. Whenever possible, ma-
terials should also be collected for the preparation of cell
blocks that can be used to cut multiple sections stained with
HE, various histochemical stains, and immunostains. In cases
where a diagnosis of malignant lymphoma is being consid-
ered, materials should be collected in media appropriate for
flow cytometry (such as Roswell Park Memorial Institute
media fluid).
Pathological Interpretation and Reporting of
Mediastinal FNA Biopsies
There are no available evidence-based or expert-con-
sensus guidelines for the interpretation of mediastinal FNA
biopsies.4,5,7 The diagnosis can be rendered using synoptic
reports or narrative reports, depending on the preferences of
each pathologist, but should include a statement regarding
specimen adequacy (Table 3). In contrast to other biopsy sites
(e.g., thyroid), it is not possible to recommend quantitative
criteria, such as a minimum number of cells or cell clusters,
to assess the adequacy of a needle biopsy of a mediastinal
lesion. It is recommended that the cytological findings be
correlated with the clinical and imaging findings to establish
whether the available cytological materials are sufficient to
render a specific diagnosis or a clinically applicable differ-
ential diagnosis.
It is important that FNA biopsies of mediastinal lesions
be closely correlated with imaging findings and the clinical
differential diagnosis, so that the report provides clinically
relevant information.4,7 In patients where malignant lym-
phoma is being considered in the differential diagnosis,
information regarding immunostains and flow cytometry in-
formation should be incorporated in the cytological report.22
Immunostains are particularly helpful for the diagnosis
of mediastinal tumors using FNA biopsies.1 Immunostains
for keratin AE1/AE3 are helpful to confirm the presence of
epithelial cells that may be present in lesions located near the
thymus but are not diagnostic of thymic tumors. Immunos-
tains for -fetoprotein, human chorionic gonadotropin, pla-
cental alkaline acid phosphatase, and OCT 3/4 are helpful for
differentiating germ cell tumors from thymic tumors. Table 4
lists various immunostains that can be helpful for the diag-
nosis of selected mediastinal lesions.
It is recommended that pathologists who diagnose
FNA biopsies of the mediastinum infrequently, or are
uncertain about a particular diagnosis for other reasons,
review the slides with another colleague or consult with an
expert with experience in the interpretation of mediastinal
lesions. FNA biopsy results should be interpreted with cau-
tion because of the heterogeneous nature of many mediastinal
tumors and the limited amount of tissue obtained. Accurate
subclassification of thymomas and selected malignant lym-
phomas is often not possible on a FNA biopsy. In particular,
classification of the World Health Organization (WHO) sub- TA
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type of thymoma from an FNA should probably be avoided,
as an accurate assessment is difficult even with resected
specimens unless multiple areas are examined because of
tumor heterogeneity.23–25
MEDIASTINAL NEEDLE CORE BIOPSIES
Technical Aspects
Nineteen-gauge Trucut needles have been generally
used for the collection of core biopsies.12,17,20 An 18-gauge
BioPince needle has been used successfully for both FNA and
core biopsies.12 On the basis of these results, we suggest that
a reasonable minimal baseline is the use of 19-gauge needles
to obtain transthoracic core biopsies (Table 5).
There are also no guidelines or standards regarding a
required minimum number of cores during the performance
of transthoracic needle biopsies. In our experience, a mini-
mum of three biopsy cores provides adequate materials in
most patients, and we propose that this be adopted as the
standard policy.
Core biopsies are generally fixed in formalin, cut, and
stained with HE, and various ancillary histochemical and immu-
nostains are used if necessary.16,18,21 The nature and number of
histochemical and immunostains varies according to the path-
ological findings encountered in a biopsy.
Pathological Interpretation and Reporting
There are no available evidence-based or expert-con-
sensus guidelines for the interpretation of needle core biop-
sies of the mediastinum.12,17,20 The diagnosis can be rendered
using synoptic reports or narrative reports depending on the
preferences of each pathologist. Biopsy findings should be
closely correlated with the imaging findings and other clinical
information, and pathologists should strive to provide a
specific diagnosis or a differential diagnosis rather than a
histological description of pathological findings. Neverthe-
less, pathologists should be aware that mediastinal tumors,
particularly thymomas, can be heterogeneous and include
information in a “Comment” section, providing their clinical
colleagues with a brief discussion of the potential limitations
and pitfalls of a particular diagnosis.
The immunostains listed in Table 4 are also helpful for
the diagnosis of mediastinal core biopsies. It is recommended
that pathologists who diagnose needle core biopsies of the
mediastinum infrequently, or be uncertain about a particular
diagnosis for other reasons, review the slides with another
colleague or consult with an expert with experience in the
interpretation of mediastinal lesions.
Core needle biopsy results should be interpreted with
caution. Accurate subclassification of cell type in lesions such
as thymomas and selected malignant lymphomas is often not
possible on a needle core biopsy, because these lesions are
frequently heterogeneous. Regarding subclassification of thy-
momas, this should probably not be considered conclusive
based on a core needle biopsy. Although there are no data
defining the accuracy of identifying the subtype, it is likely
limited, given that even with resected specimens’ multiple areas
must be examined to provide an accurate assessment.23–25
SURGICAL BIOPSIES OF MEDIASTINAL
LESIONS
Technical Aspects
In general, surgical biopsies (mediastinotomy, medias-
tinoscopy, VATS, or minithoracotomy) provide the patholo-
gist with larger samples that can be diagnosed with less
difficulty than FNA or needle core biopsies.8 Nevertheless, it
is crucial that enough representative tissue is obtained.
Very often, surgical incisional biopsies of mediastinal
lesions are sent for frozen section.19 As the frozen section
procedure introduces technical artifacts that can preclude
adequate diagnoses, it is important that thoracic surgeons be
reminded at the time of intraoperative consultation of the
need to submit additional tissues that are fixed in formalin or
other adequate fixative and are not processed for frozen
section (Table 6). Furthermore, frozen-section diagnoses
should be interpreted cautiously, especially in influencing a
decision to proceed with resection.23
In general, multiple biopsies of a mediastinal mass are
helpful once an initial portion is frozen to assess adequacy.
This is a consequence of the intrinsic heterogeneity of thy-
moma morphology and subclassification and also for those
mixed tumors of thymoma and thymic carcinoma. The same
holds true for other tumors in the differential diagnosis such
as mixed germ cell neoplasms and thymic neuroendocrine
tumors, which can be quite heterogeneous. Multiple biopsies
also allow one to avoid zones of cystic degeneration or
TABLE 5. Policies Regarding Needle Core Biopsies of
Mediastinal Lesions
Technical aspects when obtaining needle core needle biopsies
19 gauge needle (or larger)
Three passes (or more)
Interpretation and reporting of needle core biopsies
Interpretation should be correlated with clinical and radiologic findings
Immunostains should be used as suggested by the differential diagnosis
Consultation with an experienced second pathologist is recommended
whenever there is any diagnostic difficulty
TABLE 6. Policies Regarding Surgical Incisional Biopsies of
Mediastinal Lesions
Technical aspects when obtaining incisional biopsies
Frozen section is useful to assess whether the tissue is representative
Frozen section diagnoses should be interpreted cautiously
Additional tissue not processed for frozen section should be obtained
Multiple biopsies are recommended because of frequent heterogeneity
of mediastinal tumors
Biopsies that are deep rather than wide are suggested
Policies in interpretation and reporting of surgical incisional biopsies
Interpretation should be correlated with clinical and radiologic findings
Consultation with an experienced second pathologist is recommended
whenever there is any diagnostic difficulty
Immunostains may be helpful in addressing issues related to subtyping
of thymic malignancies and differentiation from other mediastinal
malignancies
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necrosis that may obscure the diagnosis. If possible, a 1-cm-
cubed portion of the mediastinal mass should be sent for flow
cytometry, especially if non-Hodgkin lymphoma is in the
differential diagnosis. (Touch preps of the biopsy specimen
may also be helpful.)
Incisional biopsies should be deep rather than wide in
their configuration as one must penetrate thick thymic capsule
and pass through any compressed normal thymus gland that
can be confused with thymoma resulting in a false diagnosis
(if the tumor is not a thymoma) or a false designation as
“invasive.”
Pathological Interpretation and Reporting of
Mediastinal Incisional Biopsies
Surgical biopsy specimens are handled in the laboratory
as other surgical pathology specimens. It is recommended
that the biopsy results be closely correlated with the imaging
findings, as described earlier, and reviewed by a second
pathologist whenever there are any uncertainties about the
interpretation of the pathological findings (Table 6).
Superficially, the diagnosis of thymoma seems rather
simple, and yet, depending on the perspective of the surgeon
and the medical oncologist, additional immunohistochemical
stains may be necessary. Several differential diagnostic prob-
lems may need to be confronted, with each potentially re-
quiring additional studies and implying a different surgical or
medical therapy:
1. Thymic hyperplasia versus thymoma.
2. WHO subtyping of thymoma.
3. Thymoma versus thymic carcinoma.
4. Thymoma versus thymic neuroendocrine neoplasms.
5. Subtyping thymic carcinoma especially small cell car-
cinoma.
6. Thymic epithelial tumors versus metastases or other
primary tumors of the mediastinum.
Immunohistochemistry is the predominant method by
which these diagnostic problems are resolved. If routine
histopathology and history is not classical, immunohisto-
chemical stains require adequate fixation of diagnostic mate-
rial usually in buffered 10% formalin.1 Thymomas are cytok-
eratin-positive epithelial proliferations associated with a
variably intense lymphocytic infiltrate with the epithelial cells
having elongated cell processes that interanastomose in a
complex arborizing spiderweb-like network. These epithelial
cells express a variety of epithelial antigens including CEA,
Ber EP4, CD15, and calretinin. The lymphoid component of
most thymomas is primarily composed of T cells with rare B
cells, with the T cells often having an immature phenotype
expressing CD3, CD5, CD43, CD1a, CD99, Tdt, CD10, and
Bcl2. It should be noted that an immature phenotype overlaps
with that of normal thymus, thymic hyperplasia, and lympho-
blastic lymphoma. With this background and with the use of
Table 4, the six major problem areas can be addressed.
Some clinicians may base therapeutic decisions on
WHO subtypes. In general, in type A thymoma, the epithelial
cells may aberrantly express CD20.26 Type B3 thymomas, in
contrast to other varieties, may express epithelial membrane
antigen, mutant p53 protein, and, occasionally, CD5.
The distinction between thymoma (especially B3),
thymic neuroendocrine neoplasms, and lymphoepithelio-
ma-like thymic carcinoma is usually made on morphologic
grounds. Nevertheless, in difficult cases, immunohisto-
chemistry may influence this decision. In particular, CD5,
CD117 (especially coexpression of CD5 and CD117),
CD70, and mutant P53 expression are more often seen in
thymic carcinomas. Similarly, synaptophysin, CD56, and
chromogranin are more often seen in thymic neuroendo-
crine carcinomas. The proliferative activity of thymic
carcinoma with Ki67 stains may also be influential as it is
usually much greater than in thymoma. It should be noted,
however, that the lymphoid cells of thymomas can dem-
onstrate strong Ki67 positivity, and the distinction of
mitotic activity of the epithelial component from the lym-
phocytic component is essential.
In addition, organ-specific or neuroendocrine stain such
as TTF-1, CDX-2, calcitonin, and prostatic specific antigen,
among others, can help to exclude metastases to the anterior
mediastinum that mimic primary neuroendocrine and other
thymic neoplasias. Within the realm of thymic carcinoma,
there is a wide variety of carcinomas that may require special
histochemical and immunohistochemical stains, once the di-
agnosis of carcinoma is made.
Thymic epithelial tumors can be confused with malig-
nant lymphomas including lymphoblastic lymphomas, small
lymphoid proliferations, and Hodgkin disease. In general,
cytokeratin and CD45 stains are helpful in screening hema-
tolymphoid proliferations into specific subgroups. Within the
non-Hodgkin lymphoma category, a comprehensive panel of
immunostains may be applied (not discussed in this article),
and for this reason, flow cytometry is worthwhile. For Hodg-
kin lymphoma, CD30, CD15, PAX5, and EBER probes for
Epstein Barr Virus can be helpful. Germ cell tumors espe-
cially seminoma, embryonal carcinoma, and yolk sac tumor
must be considered in young individuals. Seminomas weakly
express cytokeratin in 20% of cases and are positive for OCT
3/4, placental alkaline phosphatase, and podoplanin. Embry-
onal carcinomas are cytokeratin positive but express CD30
and OCT 3/4. Yolk sac tumors are also cytokeratin positive
but express -fetoprotein and occasionally CD30. The entire
spectrum of mesothelioma and sarcoma can be seen in the
anterior mediastinum requiring unique antibody panels not
discussed in this article.
Perhaps, the most important differential diagnostic con-
sideration would be metastases to the thymus gland or me-
diastinal lymph nodes. The most common consideration
would be non-small cell carcinoma of the lung, and for this
distinction, TTF-1, napsin, and surfactant apoprotein stains
are helpful. Thyroid carcinomas extending into the mediasti-
num could be approached with thyroglobulin and PAX8
immunostains. Metastatic mammary carcinoma is usually
gross cystic disease fluid protein-15 and mammaglobin pos-
itive with positive estrogen and progesterone receptors. Met-
astatic melanoma is always in the differential diagnosis, and
S100 protein, HMB45, and melan-A immunoperoxidase stud-
ies help to address this possibility.
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CONCLUSION
Although much of the literature on management of
patients with thymic malignancies has focused on patholog-
ical (postoperative) data, most clinical management decisions
are made preoperatively, which makes it quite important how
small biopsies are evaluated and interpreted. This article
summarizes the data pertaining to this and proposes guide-
lines for the technical performance, interpretation, and report-
ing on small biopsies of anterior mediastinal masses. Follow-
ing these policies will provide a more consistent and
evidenced-based approach to patient management. Further-
more, following these policies in a consistent manner will
allow data to be compared and collaborative research to be
done, taking advantage of a global medical community.
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